Parathyroid Diseases Clinical Trial
Official title:
Localization of Parathyroid Adenomas Using MRI and SPECT Fusion Software in Patients With Persistent or Recurrent Hyperparathyroidism
The purpose of this study is to design a method to better localize parathyroid adenomas. This study will include approximately 6 patients who have not had surgery and another 25 patients who have already had surgery over the course of one year.
While a successful neck exploration for PHP is primarily dependent on the experience of the
surgeon, there are currently several localizing studies available to increase success.
Although the necessity of localizing studies pre-operatively for first time neck
explorations is still under debate, there is no question of their importance for persistent
or recurrent PHP that requires re-operation. Localizing studies in these patients have been
clearly shown to reduce operating time, avoid unnecessary dissection, reduce morbidity, and
improve success rate.
Several modalities have been employed for localization such as ultrasound (US), computed
tomography (CT), and magnetic resonance imaging (MRI). The sensitivity of ultrasound for the
preoperative detection of parathyroid adenomas has been reported to be 65-90% (1). There are
however, limitations to US. Because of the sonolucent appearance of parathyroid adenomas, it
is impossible to distinguish an ectopic cervical parathyroid adenoma from a pathologic lymph
node. Furthermore, mediastinal parathyroid adenomas are difficult, if not impossible to
visualize due to acoustic shadowing from the sternum and clavicles (2). Also, this method is
very operator-dependent. MRI has a slightly higher sensitivity of 62.5-94% while CT has a
poor sensitivity of only 40-44% (1).
We are using dual-phase single photon emission tomography (SPECT) imaging with technetium
99m sestamibi and visual thyroid subtraction with technetium 99m as pertechnetate. This
method can achieve sensitivities of 68-95% and specificities of 75-100% (1). SPECT imaging
is dependent on the differential washout of sestamibi between normal thyroid tissue and
abnormal parathyroid tissue. Theoretically, sestamibi will washout of normal thyroid tissue
much more quickly than it will from abnormal parathyroid tissue. Therefore, SPECT imaging is
usually performed immediately and then at 90 and 180 minutes after sestamibi injection.
SPECT imaging, however, has several limitations, not the least of which is its inability to
provide discrete anatomic detail.
In addition, we will use a control group of patients who have parathyroid adenomas but who
have not yet had surgery to test the efficacy of our fusion software.
Our goal is to acquire MRI and SPECT imaging with fiducial markers and utilize fusion
software to create a detailed anatomic map of the neck for more accurate localization of the
lesion.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04589884 -
Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
|
||
Completed |
NCT00569920 -
Nausea and Pain Prophylaxis During Thyroid Surgery
|
N/A | |
Completed |
NCT04704349 -
Latest Imaging SPECT System Evaluation Phase 1
|
N/A | |
Completed |
NCT03747029 -
Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
|
||
Completed |
NCT03640247 -
Pain Medications Following Thyroidectomy and Parathyroidectomy
|
Phase 1 | |
Completed |
NCT03555487 -
Clinical Value of 18F-FCH PET in Localizing Parathyroid Lesions: Comparison With MIBI Scan.
|
Phase 3 | |
Completed |
NCT04344886 -
Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery
|
N/A | |
Completed |
NCT03469310 -
Minimizing Narcotic Analgesics After Endocrine Surgery
|
Phase 4 | |
Not yet recruiting |
NCT05243979 -
The Relation Between Thyroid , Parathyroid Hormones and eGFR in CKD Patients in Assiut
|
||
Active, not recruiting |
NCT05778071 -
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
|
Phase 3 | |
Completed |
NCT02901873 -
EIS in Thyroid and Parathyroid Surgery
|
N/A | |
Recruiting |
NCT04569513 -
The Analysis of Thyroidectomy and Parathyroidectomy
|
||
Recruiting |
NCT05387070 -
PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism
|
Phase 3 | |
Not yet recruiting |
NCT05432050 -
Bispectral Index and Patient State Index During General Anesthesia With Remimazolam
|
||
Recruiting |
NCT06274970 -
PaThERAS: ERAS Protocols in Thyroid & Parathyroid Surgery
|
N/A | |
Enrolling by invitation |
NCT05294393 -
Ropivacaine Plus Magnesium Sulphate Infiltration
|
Phase 4 | |
Terminated |
NCT04745793 -
Precise Recognition With Enhanced Vision of Endocrine Neck Targets
|
||
Recruiting |
NCT05152927 -
Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
|
N/A | |
Active, not recruiting |
NCT04701203 -
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism
|
Phase 3 | |
Recruiting |
NCT05022667 -
Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy
|
N/A |